- Home
- DSP vs SLS Comparison
DSP vs SLS Comparison
Compare DSP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSP | SLS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 208.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DSP | SLS |
|---|---|---|
| Price | $11.74 | $3.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $18.50 | $7.00 |
| AVG Volume (30 Days) | 190.7K | ★ 11.5M |
| Earning Date | 03-02-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $324,131,000.00 | N/A |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $17.72 | N/A |
| P/E Ratio | $120.03 | ★ N/A |
| Revenue Growth | ★ 22.97 | N/A |
| 52 Week Low | $8.11 | $0.95 |
| 52 Week High | $26.33 | $5.18 |
Technical Indicators
Market Signals| Indicator | DSP | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 50.87 |
| Support Level | $12.14 | $3.69 |
| Resistance Level | $13.15 | $4.67 |
| Average True Range (ATR) | 0.63 | 0.46 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 33.02 | 29.58 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.